Elevated circulating microRNA-210 levels in patients with hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations: A potential new biomarker

Biomarkers

Volumn 18, Issue 1, 2013, Pages 23-29

  Zhang, Qiuwang ^a   Kandic, Ivana ^a   Faughnan, Marie E ^a   Kutryk, Michael J ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Biomarker; Hereditary hemorrhagic telangiectasia; MicroRNA; Pulmonary arteriovenous malformation; Real time RT PCR

Indexed keywords

MICRORNA; MICRORNA 210;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; GENOTYPE; HUMAN; LUNG ANGIOGRAPHY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PULMONARY ARTERIOVENOUS FISTULA; REAL TIME POLYMERASE CHAIN REACTION; RENDU OSLER WEBER DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING TEST;

ADULT; AGED; ARTERIOVENOUS MALFORMATIONS; HUMANS; LUNG; MICRORNAS; MIDDLE AGED; PULMONARY ARTERY; PULMONARY VEINS; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 84872572106     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.728624     Document Type: Article

References (45)

1. Ambros V. (2004). The functions of animal microRNAs. Nature 431:350-355.
2. Bartel DP. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297.
3. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, Burchfield J, Fox H, Doebele C, Ohtani K, Chavakis E, Potente M, Tjwa M, Urbich C, Zeiher AM, Dimmeler S. (2009). MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324:1710-1713.
4. Bourdeau A, Dumont DJ, Letarte M. (1999). A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 104:1343-1351.
5. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Ragoussis J. (2008). hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 14:1340-1348.
6. Chan SY, Loscalzo J. (2010). MicroRNA-210: A unique and pleiotropic hypoxamir. Cell Cycle 9:1072-1083.
7. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. (2009). MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 69:1221-1229.
8. Cui H, Grosso S, Schelter F, Mari B, Kruger A. (2012). On the Pro-Metastatic Stress Response to Cancer Therapies: Evidence for a Positive Co-Operation between TIMP-1, HIF-1a, and miR-210. Front Pharmacol 3:134.
9. D'Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG, Rubino M, Carena MC, Spazzafumo L, De Simone M, Micheli B, Biglioli P, Achilli F, Martelli F, Maggiolini S, Marenzi G, Pompilio G, Capogrossi MC. (2010). Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 31:2765-2773.
10. Fang Y, Shi C, Manduchi E, Civelek M, Davies PF. (2010). MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci USA 107:13450-13455.
11. Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G, Capogrossi MC, Martelli F. (2008). MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 283:15878-15883.
12. Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, Spears J, Brown DH, Buscarini E, Chesnutt MS, Cottin V, Ganguly A, Gossage JR, Guttmacher AE, Hyland RH, Kennedy SJ, Korzenik J, Mager JJ, Ozanne AP, Piccirillo JF, Picus D, Plauchu H, Porteous ME, Pyeritz RE, Ross DA, Sabba C, Swanson K, Terry P, Wallace MC, Westermann CJ, White RI, Young LH, Zarrabeitia R; HHT Foundation International - Guidelines Working Group. (2011). International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 48:73-87.
13. Fernandez-L A, Garrido-Martin EM, Sanz-Rodriguez F, Pericacho M, Rodriguez-Barbero A, Eleno N, Lopez-Novoa JM, Duwell A, Vega MA, Bernabeu C, Botella LM. (2007). Gene expression fingerprinting for human hereditary hemorrhagic telangiectasia. Hum Mol Genet 16:1515-1533.
14. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Roxe T, Muller-Ardogan M, Bonauer A, Zeiher AM, Dimmeler S. (2010). Circulating microRNAs in patients with coronary artery disease. Circ Res 107:677-684.
15. Fish JE, Wythe JD, Xiao T, Bruneau BG, Stainier DY, Srivastava D, Woo S. (2011). A Slit/miR-218/Robo regulatory loop is required during heart tube formation in zebrafish. Development 138:1409-1419.
16. Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, Homer J, Corbridge R, Cox G, West CM, Ragoussis J, Harris AL. (2010). hsamir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer 116:2148-2158.
17. Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J, Hasegawa K, Li C, O'Brien-Jenkins A, Katsaros D, Weber BL, Simon C, Coukos G, Zhang L. (2008). miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 7:255-264.
18. Giordano P, Lenato GM, Pierucci P, Suppressa P, Altomare M, Del Vecchio G, Di Bitonto G, De Mattia D, Guanti G, Sabba C. (2009). Effects of VEGF on phenotypic severity in children with hereditary hemorrhagic telangiectasia. J Pediatr Hematol Oncol 31:577-582.
19. Govani FS, Shovlin CL. (2009). Hereditary haemorrhagic telangiectasia: A clinical and scientific review. Eur J Hum Genet 17:860-871.
20. Greither T, Wurl P, Grochola L, Bond G, Bache M, Kappler M, Lautenschlager C, Holzhausen HJ, Wach S, Eckert AW, Taubert H. (2012). Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. Int J Cancer 130:1230-1235.
21. Guttmacher AE, Marchuk DA, White RI Jr. (1995). Hereditary hemorrhagic telangiectasia. N Engl J Med 333:918-924.
22. Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D, Ji Y, Zhao C, Wang J, Yang BB, Zhang Y. (2006). MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS ONE 1:e116.
23. Ito T, Yagi S, Yamakuchi M. (2010). MicroRNA-34a regulation of endothelial senescence. Biochem Biophys Res Commun 398:735-740.
24. Ji F, Yang B, Peng X, Ding H, You H, Tien P. (2011). Circulating microRNAs in hepatitis B virus-infected patients. J Viral Hepat 18:e242-e251.
25. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, Guttmacher AE, Jackson CE, Attisano L, Kucherlapati R, Porteous ME, Marchuk DA. (1996). Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13:189-195.
26. Kelly TJ, Souza AL, Clish CB, Puigserver P. (2011). A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol Cell Biol 31:2696-2706.
27. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA, Ivan M. (2007). A microRNA signature of hypoxia. Mol Cell Biol 27:1859-1867.
28. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, Mummery C, Arthur HM, ten Dijke P. (2004). Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23:4018-4028.
29. Lee RC, Feinbaum RL, Ambros V. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843-854.
30. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J. (1994). Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8:345-351.
31. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513-10518.
32. Ojeda-Fernandez L, Barrios L, Rodriguez-Barbero A, Recio-Poveda L, Bernabeu C, Botella LM. (2010). Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT). Clin Chim Acta 411:494-499.
33. Park SO, Wankhede M, Lee YJ, Choi EJ, Fliess N, Choe SW, Oh SH, Walter G, Raizada MK, Sorg BS, Oh SP. (2009). Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest 119:3487-3496.
34. Plauchu H, de Chadarevian JP, Bideau A, Robert JM. (1989). Agerelated clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 32:291-297.
35. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, Mercatanti A, Hammond S, Rainaldi G. (2006). MicroRNAs modulate the angiogenic properties of HUVECs. Blood 108:3068-3071.
36. Pulkkinen K, Malm T, Turunen M, Koistinaho J, Yla-Herttuala S. (2008). Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett 582:2397-2401.
37. Qi J, Qiao Y, Wang P, Li S, Zhao W, Gao C. (2012). microRNA-210 negatively regulates LPS-induced production of proinflammatory cytokines by targeting NF-?B1 in murine macrophages. FEBS Lett 586:1201-1207.
38. Rothe F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL, Piccart M, Sotiriou C. (2011). Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS ONE 6:e20980.
39. Shovlin CL. (2010). Hereditary haemorrhagic telangiectasia: Pathophysiology, diagnosis and treatment. Blood Rev 24:203-219.
40. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H. (2000). Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91:66-67.
41. Srinivasan S, Hanes MA, Dickens T, Porteous ME, Oh SP, Hale LP, Marchuk DA. (2003). A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet 12:473-482.
42. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R, Olson EN. (2008). The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 15:261-271.
43. Wightman B, Ha I, Ruvkun G. (1993). Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75:855-862.
44. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J, Mayr M. (2010). Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 107:810-817.
45. Zhang Z, Sun H, Dai H, Walsh RM, Imakura M, Schelter J, Burchard J, Dai X, Chang AN, Diaz RL, Marszalek JR, Bartz SR, Carleton M, Cleary MA, Linsley PS, Grandori C. (2009). MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 8:2756-2768.